<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709576</url>
  </required_header>
  <id_info>
    <org_study_id>PSCI 17-056</org_study_id>
    <nct_id>NCT03709576</nct_id>
  </id_info>
  <brief_title>Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML</brief_title>
  <official_title>A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out the toxicity and efficacy of a combination of&#xD;
      Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant&#xD;
      maintenance therapy for non-remission AML and to see the overall diseases free survival,&#xD;
      relapse, and GVHD after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical studies Pevonedistat has shown significant single agent activity against mouse&#xD;
      xenograft models of AML cell Line HL-60. Also this effect seemed to be synergistically&#xD;
      enhanced by combining it with Azacitidine. In clinical arena, Pevonedistat has shown single&#xD;
      agent activity in heavily pretreated patients with AML. In Study C15003, responses (complete&#xD;
      responses [CRs] and partial responses [PRs]) were observed in a variety of patient settings,&#xD;
      including post allogeneic transplant, therapy-related AML, and primary refractory AML,&#xD;
      although some of the responses were of relatively short duration. Study C15009 is an ongoing&#xD;
      phase 1b study evaluating the MTD of Pevonedistat on Days 1, 3, and 5 in combination with 75&#xD;
      mg/m2 Azacitidine (administered on a 5-on/2-off [weekend]/2-on schedule) in a 28-day&#xD;
      treatment cycle in patients 60 years of age or older with treatment naïve AML who are&#xD;
      unlikely to benefit from standard induction therapy. As of 22 June 2017, enrollment had&#xD;
      completed and 15 patients remained on study. As of 22 January 2017, preliminary data are&#xD;
      available for 64 patients enrolled in the study who received at least 1 dose of Pevonedistat&#xD;
      in combination with Azacitidine; these patients had completed a total of approximately 360&#xD;
      cycles, with a median of 4 cycles of treatment In the dose escalation cohorts, 6 patients&#xD;
      received 20 mg/m2 Pevonedistat, and 3 patients received 30 mg/m2. The most common events&#xD;
      (reported by ≥ 25% of patients) were constipation (45%), nausea (42%), fatigue (39%), anemia&#xD;
      (34%), febrile neutropenia (30%), decreased appetite (28%), and thrombocytopenia (27%). The&#xD;
      MTD in this study was determined to be 20 mg/m2 Pevonedistat given on Days 1, 3, and 5, in&#xD;
      combination with 75 mg/m2 Azacitidine given on Days 1 through 5, 8, and 9, in 28 day&#xD;
      treatment cycles. A total of 45 (70%) patients experienced at least 1 SAE A total of 14 SAEs&#xD;
      were reported for more than 1 patient, including: febrile neutropenia (16 patients);&#xD;
      pneumonia (8 patients); pyrexia (4 patients); AML and sepsis (3 patients); and acute&#xD;
      myocardial infarction, cellulitis, diverticulitis, dyspnea, embolism, hypoxia, mental status&#xD;
      changes, multi-organ failure, and transaminase increased (2 patients each). A total of 19&#xD;
      patients treated with Pevonedistat (either 20 mg/m2 or 30 mg/m2), discontinued from Study&#xD;
      participation because of a TEAE. No other events leading to discontinuation were assessed by&#xD;
      study investigators as at least possibly related to study drug treatment. 11 on-study deaths&#xD;
      had been reported; none assessed as related to study treatment. A total of 31 patients&#xD;
      experienced PR or better. Eighteen patients had a best response of CR, 4 patients had a best&#xD;
      response of CRi, and 9 patients had a best response of PR. One patient in the 30 mg/m2 dose&#xD;
      level group achieved a CR; all other responses occurred in patients treated with 20 mg/m2.&#xD;
&#xD;
      The following studies are currently enrolling.&#xD;
&#xD;
        -  Study 2001: A Phase 2, randomized, controlled Open-Label Clinical study of the efficacy&#xD;
           and safety of Pevonedistat plus Azacitidine versus single-agent Azacitidine in patients&#xD;
           with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia and&#xD;
           low-blast acute myelogenous leukemia.&#xD;
&#xD;
        -  Study 1012: A phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single&#xD;
           Agent and in Combination with Azacitidine in adult East Asian patients with acute&#xD;
           myeloid leukemia or myelodysplastic syndromes&#xD;
&#xD;
      Hence owing to the current knowledge of clinical and preclinical experience with Azacitidine&#xD;
      and Pevonedistat alone and in combination, this combination appears feasible for testing in&#xD;
      patients post-transplant with at very high risk of relapse.&#xD;
&#xD;
      The Investigator proposes a study using a combination of Pevonedistat and Azacitidine for&#xD;
      maintenance therapy after allogeneic HSCT for non-remission. Patients will receive up to five&#xD;
      28 day cycles of the investigational maintenance therapy. Maintenance therapy will begin&#xD;
      between days +30 to +45 post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding pulled&#xD;
  </why_stopped>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One Year Overall Survival Assessed by the Kaplan-Meier Plots</measure>
    <time_frame>1 year</time_frame>
    <description>One year overall survival assess by Kaplan Meier Plots</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Assess the Toxicity and Efficacy of a Combination of Pevonedistat and Azacitidine as Post Allogeneic Hematopoietic Stem Cell Transplant Maintenance Therapy for Non-remission AML.</measure>
    <time_frame>not analyzed</time_frame>
    <description>Toxicity and efficacy unable to be determined as trial was closed by the sponsor prior to meeting this objective.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity Related to Pevonedistat</measure>
    <time_frame>not analyzed</time_frame>
    <description>Toxicity related to Pevonedistat unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the Overall Disease Free Survival, Relapse, and GVHD After the Above Noted Treatment</measure>
    <time_frame>not analyzed</time_frame>
    <description>overall disease free survival, relapse and GVHD unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year Disease-free Survival</measure>
    <time_frame>not analyzed</time_frame>
    <description>One-year disease-free survival unable to be determined as trail was closed by the sponsor prior to meeting this endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Relapse at 2 Years</measure>
    <time_frame>not analyzed</time_frame>
    <description>Cumulative incidence of relapse at 2 years unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two-year and Five-year Disease-free and Overall Survival</measure>
    <time_frame>not analyzed</time_frame>
    <description>Two-year and five-year disease-free and overall survival unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Mortality/Morbidity</measure>
    <time_frame>not analyzed</time_frame>
    <description>Treatment related mortality/morbidity unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Acute and Chronic GVHD</measure>
    <time_frame>not analyzed</time_frame>
    <description>Incidence and severity of acute and chronic GVHD unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Pevonedistat and Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pevonedistat</intervention_name>
    <description>To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.</description>
    <arm_group_label>Pevonedistat and Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transplant</intervention_name>
    <description>Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.</description>
    <arm_group_label>Pevonedistat and Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.</description>
    <arm_group_label>Pevonedistat and Azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years (or age of majority at participating site, whichever is greater) and ≤&#xD;
             70 years.&#xD;
&#xD;
          2. Non-remission AML at the time of transplant proven via bone marrow aspiration and/or&#xD;
             biopsy.&#xD;
&#xD;
             o&quot;Not in remission&quot; is defined as &quot;greater than 5.0% bone marrow blasts by aspirate&#xD;
             morphology,&quot; as determined by a bone marrow aspirate obtained within 2 weeks of study&#xD;
             registration.&#xD;
&#xD;
               -  For primary induction failure patients: Patients must have failed at least 2&#xD;
                  induction regimens.&#xD;
&#xD;
               -  For patients with relapsed disease: Patients who relapse more than 6 months after&#xD;
                  preceding remission must fail at least one reinduction regimen to be eligible.&#xD;
                  For patients in whom the preceding remission is equal to or shorter than 6 months&#xD;
                  duration, no re-induction regimen is required to qualify for this protocol.&#xD;
&#xD;
               -  If the pre-transplant bone marrow aspirate and biopsy are hypo plastic (less than&#xD;
                  10% cellularity), and blast percentages cannot be determined, the patient is&#xD;
                  eligible if the preceding bone marrow met the above criteria.&#xD;
&#xD;
               -  Patients with peripheral circulating blasts or patients with extramedullary&#xD;
                  leukemia are eligible if bone marrow aspirate and biopsy meets the above&#xD;
                  criteria.&#xD;
&#xD;
          3. Karnofsky Performance Scale (KPS) above or equal to 70%&#xD;
&#xD;
          4. Clinical laboratory values within the following parameters (repeat if more than 3 days&#xD;
             before the first dose):&#xD;
&#xD;
               1. Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
               2. Hemoglobin &gt; 8 g/dL. Patients may be transfused to achieve this value.&#xD;
&#xD;
               3. White blood cell (WBC) count &lt; 50,000/µL before administration of Pevonedistat on&#xD;
                  Cycle 1 Day 1. Note: Hydroxyurea may be used to control the level of circulating&#xD;
                  leukemic blast cell counts to not lower than 10,000/µL during the study.&#xD;
&#xD;
               4. LFTs (ALT, AST) equal or less than 2.5 times upper limit of normal value.&#xD;
&#xD;
               5. Bilirubin ≤ x 1.5 ULN limit&#xD;
&#xD;
          5. Female patients who:&#xD;
&#xD;
               -  Are postmenopausal (see Appendix for definition) for at least 1 year before the&#xD;
                  screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
             If they are of childbearing potential:&#xD;
&#xD;
               -  Agree to practice 1 highly effective method and 1 additional effective (barrier)&#xD;
                  method of contraception (see Appendix), at the same time, from the time of&#xD;
                  signing the informed consent through 4 months after the last dose of study drug&#xD;
                  (female and male condoms should not be used together), or&#xD;
&#xD;
               -  Agree to practice true abstinence, when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, post ovulation methods] withdrawal, spermicides only, and&#xD;
                  lactational amenorrhea are not acceptable methods of contraception.)&#xD;
&#xD;
             Male patients, even if surgically sterilized (i.e., status post vasectomy), who:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 4 months after the last dose of study drug (female&#xD;
                  and male condoms should not be used together), or&#xD;
&#xD;
               -  Agree to practice true abstinence, when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, post ovulation methods for the female partner] withdrawal,&#xD;
                  spermicides only, and lactational amenorrhea are not acceptable methods of&#xD;
                  contraception.)&#xD;
&#xD;
          6. Voluntary written consent must be given before performance of any study related&#xD;
             procedure not part of standard medical care, with the understanding that consent may&#xD;
             be withdrawn by the patient at any time without prejudice to future medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any investigational products within 21 days of study registration.&#xD;
&#xD;
          2. Known hypersensitivity to Azacitidine.&#xD;
&#xD;
          3. Active uncontrolled infections or severe infectious disease, such as severe pneumonia,&#xD;
             meningitis, or septicemia.&#xD;
&#xD;
          4. Known central nervous system (CNS) involvement.&#xD;
&#xD;
          5. Known human immunodeficiency virus (HIV) positivity.&#xD;
&#xD;
          6. Known hepatitis B surface antigen-positive, or known active hepatitis C infection.&#xD;
&#xD;
               -  Note: Patients who have isolated positive hepatitis B core antibody (ie, in the&#xD;
                  setting of negative hepatitis B surface antigen and negative hepatitis B surface&#xD;
                  antibody) must have an undetectable hepatitis B viral load. Patients who have&#xD;
                  positive hepatitis C antibody may be included if they have an undetectable&#xD;
                  hepatitis C viral load.&#xD;
&#xD;
          7. Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of study procedures&#xD;
&#xD;
          8. Major surgery within 14 days before the first dose of any study drug or a scheduled&#xD;
             surgery during study period.&#xD;
&#xD;
          9. Diagnosed or treated for another malignancy within 2 years before randomization or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Patients with non- melanoma skin cancer or carcinoma in situ of any type are&#xD;
             not excluded if they have undergone resection.&#xD;
&#xD;
         10. Life-threatening illness unrelated to cancer.&#xD;
&#xD;
         11. Patients with uncontrolled coagulopathy or bleeding disorder.&#xD;
&#xD;
         12. Known hepatic cirrhosis or severe pre-existing hepatic impairment&#xD;
&#xD;
         13. Known cardiopulmonary disease defined as:&#xD;
&#xD;
               -  Unstable angina;&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association [NYHA] Class III or IV; see&#xD;
                  appendix);&#xD;
&#xD;
               -  Myocardial infarction (MI) within 6 months prior to first dose (patients who had&#xD;
                  ischemic heart disease such as a (ACS), MI, and/or revascularization greater than&#xD;
                  6 months before screening and who are without cardiac symptoms may enroll);&#xD;
&#xD;
               -  Cardiomyopathy;&#xD;
&#xD;
               -  Clinically significant arrhythmia:&#xD;
&#xD;
                    1. History of polymorphic ventricular fibrillation or torsade de pointes,&#xD;
&#xD;
                    2. Permanent atrial fibrillation [a fib], defined as continuous a fib for ≥ 6&#xD;
                       months,&#xD;
&#xD;
                    3. Persistent a fib, defined as sustained a fib lasting &gt; 7 days and/or&#xD;
                       requiring cardioversion in the 4 weeks before screening,&#xD;
&#xD;
                    4. Grade 3 a fib defined as symptomatic and incompletely controlled medically,&#xD;
                       or controlled with device (e.g. pacemaker), or ablation and&#xD;
&#xD;
                    5. Patients with paroxysmal a fib or &lt; Gr 3 a fib for period of at least 6&#xD;
                       months are permitted to enroll provided that their rate is controlled on a&#xD;
                       stable regimen.&#xD;
&#xD;
               -  Implantable cardioverter defibrillator;&#xD;
&#xD;
               -  Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing);&#xD;
&#xD;
               -  Pulmonary hypertension&#xD;
&#xD;
         14. Uncontrolled high blood pressure (i.e., systolic blood pressure &gt; 180 mm Hg, diastolic&#xD;
             blood pressure &gt; 95 mm Hg).&#xD;
&#xD;
         15. Prolonged rate corrected QT (QTc) interval ≥ 500 msec, calculated according to&#xD;
             institutional guidelines.&#xD;
&#xD;
         16. Left ventricular ejection fraction (LVEF) &lt; 50% as assessed by echocardiogram or&#xD;
             radionuclide angiography.&#xD;
&#xD;
         17. Known moderate to severe chronic obstructive pulmonary disease, interstitial lung&#xD;
             disease, and pulmonary fibrosis.&#xD;
&#xD;
         18. Systemic antineoplastic therapy or radiotherapy for other malignant conditions within&#xD;
             14 days before the first dose of any study drug, except for hydroxyurea.&#xD;
&#xD;
         19. Female patients who are both lactating and breastfeeding or have a positive serum&#xD;
             pregnancy test during the screening period or a positive urine pregnancy test on Day 1&#xD;
             before first dose of study drug.&#xD;
&#xD;
         20. Female patients who intend to donate eggs (ova) during the course of this study or 4&#xD;
             months after receiving their last dose of study drug(s).&#xD;
&#xD;
         21. Male patients who intend to donate sperm during the course of this study or 4 months&#xD;
             after receiving their last dose of study drug(s).&#xD;
&#xD;
         22. Patients who need to use clinically significant CYP3A enzyme inducers (listed on&#xD;
             Appendix A)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin Mineishi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Cancer Institute (Hershey Medical Center)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center: Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997 Jun 1;89(11):4226-35.</citation>
    <PMID>9166868</PMID>
  </reference>
  <reference>
    <citation>Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15;89(12):4531-6.</citation>
    <PMID>9192777</PMID>
  </reference>
  <reference>
    <citation>Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res. 2002 Apr;8(4):1014-20.</citation>
    <PMID>11948108</PMID>
  </reference>
  <reference>
    <citation>Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. Bone Marrow Transplant. 2005 Oct;36(7):565-74. Review.</citation>
    <PMID>15995714</PMID>
  </reference>
  <reference>
    <citation>Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63.</citation>
    <PMID>9446633</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <results_first_submitted>June 26, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2020</results_first_posted>
  <last_update_submitted>November 22, 2020</last_update_submitted>
  <last_update_submitted_qc>November 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Shin Mineishi</investigator_full_name>
    <investigator_title>Professor and Director, Blood and Marrow Transplant Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Pevonedistat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03709576/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Penn State Milton S. Hershey Medical Center from 18 July 2018 through 17 October 2019</recruitment_details>
      <pre_assignment_details>One subject was excluded due to progression of disease prior to enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pevonedistat and Azacitidine</title>
          <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.&#xD;
Pevonedistat: To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.&#xD;
transplant: Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>progression prior to enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This research is being done to find out the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML and to see the overall diseases free survival, relapse, and GVHD after treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Pevonedistat and Azacitidine</title>
          <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>One Year Overall Survival Assessed by the Kaplan-Meier Plots</title>
        <description>One year overall survival assess by Kaplan Meier Plots</description>
        <time_frame>1 year</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.&#xD;
Pevonedistat: To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.&#xD;
transplant: Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Overall Survival Assessed by the Kaplan-Meier Plots</title>
          <description>One year overall survival assess by Kaplan Meier Plots</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Toxicity and Efficacy of a Combination of Pevonedistat and Azacitidine as Post Allogeneic Hematopoietic Stem Cell Transplant Maintenance Therapy for Non-remission AML.</title>
        <description>Toxicity and efficacy unable to be determined as trial was closed by the sponsor prior to meeting this objective.</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Toxicity and Efficacy of a Combination of Pevonedistat and Azacitidine as Post Allogeneic Hematopoietic Stem Cell Transplant Maintenance Therapy for Non-remission AML.</title>
          <description>Toxicity and efficacy unable to be determined as trial was closed by the sponsor prior to meeting this objective.</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Toxicity Related to Pevonedistat</title>
        <description>Toxicity related to Pevonedistat unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Related to Pevonedistat</title>
          <description>Toxicity related to Pevonedistat unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Overall Disease Free Survival, Relapse, and GVHD After the Above Noted Treatment</title>
        <description>overall disease free survival, relapse and GVHD unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Overall Disease Free Survival, Relapse, and GVHD After the Above Noted Treatment</title>
          <description>overall disease free survival, relapse and GVHD unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-year Disease-free Survival</title>
        <description>One-year disease-free survival unable to be determined as trail was closed by the sponsor prior to meeting this endpoint</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Disease-free Survival</title>
          <description>One-year disease-free survival unable to be determined as trail was closed by the sponsor prior to meeting this endpoint</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Relapse at 2 Years</title>
        <description>Cumulative incidence of relapse at 2 years unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Relapse at 2 Years</title>
          <description>Cumulative incidence of relapse at 2 years unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Two-year and Five-year Disease-free and Overall Survival</title>
        <description>Two-year and five-year disease-free and overall survival unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Two-year and Five-year Disease-free and Overall Survival</title>
          <description>Two-year and five-year disease-free and overall survival unable to be determined as trial was closed by the sponsor prior to meeting this objective</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Related Mortality/Morbidity</title>
        <description>Treatment related mortality/morbidity unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Mortality/Morbidity</title>
          <description>Treatment related mortality/morbidity unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of Acute and Chronic GVHD</title>
        <description>Incidence and severity of acute and chronic GVHD unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
        <time_frame>not analyzed</time_frame>
        <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Pevonedistat and Azacitidine</title>
            <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Acute and Chronic GVHD</title>
          <description>Incidence and severity of acute and chronic GVHD unable to be determined as trial was closed by sponsor prior to meeting this objective</description>
          <population>Data could not be reported in the data table as the data were not collected due to study early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>completion of Cycle 5 day 9, up to 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pevonedistat and Azacitidine</title>
          <description>The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neck edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus infection reactivation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>activated partial thromboplastin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bullous dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>limitations to the data exist as the sponsor closed the study prior to subjects meeting study endpoints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michelle Stojanovic</name_or_title>
      <organization>Penn State Cancer Institute</organization>
      <phone>7175310003 ext 287412</phone>
      <email>mstojanovic1@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

